New Guidelines for Breast Cancer Screens Makes Some Happy, Some Mad and Most Confused

The American Cancer Society has released new guidelines for breast cancer screening. Among the changes, the new recommendations say all...

At NCI, A Continued Commitment to Supporting the Best Science

Yesterday, at the AACR annual meeting, Dr. Doug Lowy spoke directly to the research community about his goals as NCI...

HPV Vaccine Effective Against Infection at Multiple Sites, Provides Partial Protection in Women with Previous Infections

A new study from NCI researchers finds that the HPV vaccine protects young women from infection with high-risk HPV types...

Study Forecasts New Breast Cancer Cases by 2030

A new study from NCI researchers is forecasting important trends in the types and molecular makeup of breast cancer cases...

Trial Yields Positive Data on Pembrolizumab for Lung Cancer, Potential Response Biomarker

Findings from an early phase clinical trial may point to a biomarker that identifies patients with advanced non-small cell lung...

Collateral Damage: Missing Tumor Suppressor Gene Creates Opening for Cancer Treatment

Tumor cells that are missing one copy of the tumor suppressor gene TP53 often harbor another genetic alteration that may...

Regorafenib Becomes First FDA-Approved Drug for Liver Cancer in Nearly a Decade

FDA approved the kinase inhibitor regorafenib for some patients with hepatocellular carcinoma, the most common form of liver cancer. Source...

Welcome to the New Cancer.gov

NCI has launched a new, dynamic, and easier-to-use version of NCI’s main websites, Cancer.gov and its counterpart in Spanish, Cancer.gov/espanol....

Screening Rates for Several Cancers Miss Their Targets

Screening rates for breast, colorectal, and cervical cancer are lagging behind target rates set by the Healthy People 2020 program,...